NatureSeptember 17, 2026Safety
Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study
Reported by Nature. Read the original →
What the story says
The story reports on a multicenter, post-marketing cohort study that investigates the safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome.
Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
TeduglutideB · Human evidence
- Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.Human · Observational · 2026
- Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.Human · Case report · 2026
- Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.Human · Observational · 2026
What the headline doesn't tell you
- Teduglutide has 7 studies on file, 5 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.